Effects of Physiotherapy Via Telerehabilitation in Patients With COVID-19

February 27, 2024 updated by: Pooriput Waongenngarm, PT, PhD, Chulabhorn Hospital

Effects of Physiotherapy Via Telerehabilitation on Cardiopulmonary, Physical, and Psychological Functions in Patients With COVID-19: A Randomized Controlled Trial

This study aims to evaluate the effects of Physiotherapy Via Video Calls on Cardiopulmonary Functions, Physical Function, Cognitive Function, Activity Daily Livings, and Quality of Life in Patients With COVID-19.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

A 2-armed, parallel-group, randomized controlled trial was conducted at Chulabhorn Hospital, Thailand on a convenience sample of patients who tested positive for COVID-19 using RT-PCR.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
    • Bangkok
      • Lak Si, Bangkok, Thailand, 10210
        • Chulabhorn hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 20-60 years old
  • Positive in COVID-19 testing
  • Good communication and understanding
  • Independent mobility

Exclusion Criteria:

  • Cannot complete the study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
Receive an advice and a leaflet for cardiopulmonary rehabilitation.
Experimental: Physiotherapy group
Receive the physical therapy training via video call (Pulmonary training, Calisthenic exercise, Upper and lower limbs strengthening exercise, Core stabilizer exercise, Aerobic exercise) at day 3, 6, 9, 12, 16, and 21 after positive in COVID-19 testing and also receive advise and a leaflet for cardiopulmonary rehabilitation.
Behavioral: Exercise training
  1. Physical therapy training via video call
  2. An advise and a leaflet for cardiopulmonary rehabilitation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiopulmonary function
Time Frame: at day 28 and 90 after positive in COVID-19 testing
using Cardiopulmonary exercise testing (CPET)
at day 28 and 90 after positive in COVID-19 testing
Patient's quality of life
Time Frame: at day 3 and 21 after positive in COVID-19 testing
using the The World Health Organization Quality of Life (WHOQOL-BREF-THAI) 26 items; the final score ranges from 24-120; higher score means participants satisfied with the quality of life.
at day 3 and 21 after positive in COVID-19 testing
Functional capacity
Time Frame: at day 3 and 21 after positive in COVID-19 testing
using Duke Activity status index The final score ranges between zero and 58.2 points; The higher the score, the better the functional capacity.
at day 3 and 21 after positive in COVID-19 testing
Anxiety and depression
Time Frame: at day 3 and 21 after positive in COVID-19 testing
using Hospital Anxiety and Depression Scale (HADS) The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21). A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.
at day 3 and 21 after positive in COVID-19 testing
Insomnia
Time Frame: at day 3 and 21 after positive in COVID-19 testing
using Insomnia Severity Index (ISI) The final score ranges between zero and 28 points. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
at day 3 and 21 after positive in COVID-19 testing
Cognitive function
Time Frame: at day 3 and 21 after positive in COVID-19 testing
using Thai Mental State Examination The final score ranges between zero and 30 points. A score of 25 or higher is classed as normal. If the score is below 24, the result is usually considered to be abnormal, indicating possible cognitive impairment.
at day 3 and 21 after positive in COVID-19 testing
Muscle strength
Time Frame: at day 3 and 21 after positive in COVID-19 testing
using 1-minute sit to stand
at day 3 and 21 after positive in COVID-19 testing

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chulabhorn Hospital

Investigators

  • Principal Investigator: Pooriput Waongenngarm, PhD, Chulabhorn Royal Academy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 9, 2024

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

June 15, 2024

Study Registration Dates

First Submitted

February 7, 2024

First Submitted That Met QC Criteria

February 7, 2024

First Posted (Actual)

February 9, 2024

Study Record Updates

Last Update Posted (Actual)

February 28, 2024

Last Update Submitted That Met QC Criteria

February 27, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EC014/2565

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Due to the ethical restriction, investigators cannot share any individual participant data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on Exercise training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe